MAGE-A4 IHC 1F9 pharmDx
Agilent Technologies, Inc. · Decision date Sep 21, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-21 for MAGE-A4 IHC 1F9 pharmDx, filed under P230016/S004 by Agilent Technologies, Inc. The supplement is a 30-Day Notice with the recorded reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The statement describes approval for a supplier's change to the manufacturing site for a device component.
This action concerns a supplier and manufacturing-site change for a component of an immunohistochemistry antibody assay (product code SBL, Pathology), not a new approval of the assay itself. The source does not identify the affected component, the supplier, the prior or new manufacturing site, or any performance data supporting the change. Whether the approved change alters device labeling or clinical use is not stated and remains unknown from this record.
FDA approval order statement
approval for a supplier's change to the manufacturing sight for a device component
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Pathology
- Decision date
- Sep 21, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230016/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- Decision code
- OK30
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Immunohistochemistry Assay, Antibody, Melanoma-associated antigen A4.
- Applicant
- Agilent Technologies, Inc.
- Product code
- SBL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230016 · Original PMA
MAGE-A4 IHC 1F9 pharmDx
P230016/S004 received
Application receipt date recorded by FDA.
P230016/S005 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S003 · Related supplement
MAGE-A4 IHC 1F9 pharmDx
P230016/S004 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P230016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGE-A4 IHC 1F9 pharmDxP230016 | Agilent Technologies, Inc. | PMA approval | Aug 1, 2024 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S005 | Agilent Technologies, Inc. | PMA supplement | Sep 11, 2026 | FDA |
MAGE-A4 IHC 1F9 pharmDxP230016/S003 | Agilent Technologies, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Agilent Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6392 Via Real, Carpinteria, CA, 93013
Sources and methodology
- Original FDA record: P230016/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

